Foley Hoag LLP recently represented life sciences startup company Genomics Medicine Ireland Ltd (GMI)
in its 15-year partnership with U.S. pharmaceutical company AbbVie Inc. and global contract genomics organization WuXi NextCode to conduct population genomics research in Ireland and examine potential genetic triggers for major chronic diseases.
The GMI-AbbVie-WuXi NextCode partnership will sequence the genomes of 45,000 volunteers across Ireland. Data to be included will originate from people with several types of immune-mediated diseases, neurological disorders and cancer, as well as people unaffected by these diseases.
By entering into the partnership, GMI seeks to leverage its expertise in life sciences and the unique characteristics of the Irish population to discover critical insights into disease, disease progression and therapeutic response. The resulting therapies to treat and prevent these diseases will benefit patients in Ireland and around the world.
WuXi NextCODE's integrated genomics platform will be used to organize and mine a secure, scalable database of whole genome sequence and medical data to power novel disease insights, while AbbVie will utilize the research to select targets for drug development.
Founded in 2015, GMI is an Irish life-sciences company leading large-scale, population-based genome research studies across Ireland examining the relationship between genetics, health and disease. It is building a preeminent disease-specific database of population genomics. GMI's investors include ARCH Venture Partners, Polaris Partners, GV (formerly Google Ventures), the Ireland Strategic Investment Fund, and corporate partner Amgen and its subsidiary deCODE genetics.
Foley Hoag attorneys Hemmie Chang
, Karen Tepichin, Susan Abelleira,
Greg Ploussious and Colin Zick
advised GMI on the agreement.